GlassScriptPhysician profile
Phillip A Milne
NPI 1710082060
$2,270.25
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,297 · 2020: $383 · 2021: $476 · 2022: $115.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $560.21 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $499.57 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $453.24 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $218.02 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $115.26 | 2019 | |
| Sanofi-Aventis U.S. LLC | $96.99 | 2019 | |
| Medtronic Vascular, INC. | $73.34 | 2019 | |
| Novartis Pharmaceuticals Corporation | $66.37 | 2019-2021 | |
| Amgen INC. | $60.51 | 2019 | |
| Boston Scientific Corporation | $37.39 | 2019 | |
| Pfizer INC. | $37.03 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.82 | 2019-2020 | |
| Lundbeck LLC | $22.50 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phillip Milne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.